Phosphodiesterase 4D Deficiency in the Ryanodine-Receptor Complex Promotes Heart Failure and Arrhythmias  by Lehnart, Stephan E. et al.
Cell, Vol. 123, 25–35, October 7, 2005, Copyright ©2005 by Elsevier Inc. DOI 10.1016/j.cell.2005.07.030
Phosphodiesterase 4D Deficiency in the
Ryanodine-Receptor Complex Promotes
Heart Failure and Arrhythmias
Stephan E. Lehnart,1,5 Xander H.T. Wehrens,1,5
Steven Reiken,1 Sunita Warrier,3
Andriy E. Belevych,3 Robert D. Harvey,3
Wito Richter,4 S.-L. Catherine Jin,4 Marco Conti,4
and Andrew R. Marks1,2,*
1Clyde and Helen Wu Center for Molecular Cardiology
Department of Physiology and Cellular Biophysics
2Department of Medicine
College of Physicians and Surgeons of Columbia
University
New York, New York 10032
3Department of Physiology and Biophysics
Case Western Reserve University
Cleveland, Ohio 44106
4Division of Reproductive Biology
Department of Obstetrics and Gynecology
Stanford University School of Medicine
Stanford, California 94305
Summary
Phosphodiesterases (PDEs) regulate the local con-
centration of 3,5 cyclic adenosine monophosphate
(cAMP) within cells. cAMP activates the cAMP-depen-
dent protein kinase (PKA). In patients, PDE inhibitors
have been linked to heart failure and cardiac arrhyth-
mias, although the mechanisms are not understood.
We show that PDE4D gene inactivation in mice re-
sults in a progressive cardiomyopathy, accelerated
heart failure after myocardial infarction, and cardiac
arrhythmias. The phosphodiesterase 4D3 (PDE4D3)
was found in the cardiac ryanodine receptor (RyR2)/
calcium-release-channel complex (required for exci-
tation-contraction [EC] coupling in heart muscle).
PDE4D3 levels in the RyR2 complex were reduced in
failing human hearts, contributing to PKA-hyperphos-
phorylated, “leaky” RyR2 channels that promote car-
diac dysfunction and arrhythmias. Cardiac arrhyth-
mias and dysfunction associated with PDE4 inhibition
or deficiency were suppressed in mice harboring
RyR2 that cannot be PKA phosphorylated. These data
suggest that reduced PDE4D activity causes de-
fective RyR2-channel function associated with heart
failure and arrhythmias.
Introduction
Phosphodiesterases (PDEs) control the temporal and
spatial dynamics of the second messenger 3#,5# cyclic
adenosine monophosphate (cAMP), allowing for highly
localized cAMP gradients in cells (Zaccolo and Pozzan,
2002). Localization of PDEs in close proximity to cAMP-
dependent protein kinase A (PKA) is thought to control
access of cAMP to the regulatory kinase subunit (Conti
et al., 2003; Houslay and Adams, 2003). PKA phosphor-*Correspondence: arm42@columbia.edu
5 These authors contributed equally to this work.ylation of proteins mediates a wide variety of signals,
including those generated during activation of the sym-
pathetic nervous system (SNS) as part of the “fight or
flight” response. On the other hand, chronic activation
of the SNS is a characteristic finding in heart failure,
and acute stimulation of the SNS has been linked to
triggered arrhythmias associated with sudden cardiac
death.
In the heart, phosphodiesterase 4 (PDE4) contributes
to the regulation of cAMP levels in cardiac myocytes.
In particular, PDE4 cAMP-hydrolyzing activity has been
localized to the transverse (T) tubule/sarcoplasmic re-
ticulum (SR) junctional space that is involved in excita-
tion-contraction coupling (Mongillo et al., 2004; Zac-
colo and Pozzan, 2002). PDEs have been shown to
be components of macromolecular signaling com-
plexes via binding to targeting proteins including mus-
cle A-kinase anchoring proteins (AKAPs) (Dodge et al.,
2001). PDEs in cardiac muscle are complexed with pro-
teins that mediate signals from SNS, including β-adren-
ergic receptors and β-arrestin (Mongillo et al., 2004;
Perry et al., 2002; Xiang et al., 2005).
The PDE superfamily is subgrouped into 11 families
that include at least 20 genes and 50 unique isoforms.
Of these PDE families, only PDE4, PDE7, and PDE8 are
cAMP specific (Conti et al., 2003). Through alternative
splicing and the use of multiple promotors, the PDE4D
gene encodes nine variants (PDE4D1–9) with identical
catalytic domains and carboxyl termini and unique
amino termini important for subcellular localization. For
example, PDE4D3 binds to the targeting protein mAKAP
via its unique N-terminal region, creating a mAKAP-
PKA-PDE4D3 signaling module (Dodge et al., 2001;
Tasken et al., 2001) in which PKA phosphorylation in-
creases PDE4D3 activity approximately 2-fold (Carlisle
Michel et al., 2004; Sette and Conti, 1996). Moreover,
mAKAP colocalizes with the ryanodine receptor (RyR2)/
calcium-release channel in cardiac muscle (Ruehr et al.,
2003; Yang et al., 1998), where it is part of the RyR2
macromolecular signaling complex (Marx et al., 2000;
Wehrens et al., 2003).
PKA-PDE signaling has been identified as a thera-
peutic target in several major diseases (Conti et al.,
2003). Inhibitors of the PDE4 family are under develop-
ment for asthma, chronic obstructive lung disease
(COPD), cognitive disorders including Alzheimer’s dis-
ease, and stroke (Gong et al., 2004; Gretarsdottir et al.,
2003; Vignola, 2004). However, nonspecific PDE inhibi-
tion with theophylline, commonly used to treat asthma
and COPD, and trials using PDE3 inhibition to treat
heart failure have demonstrated increased mortality
due to cardiac arrhythmias (Barnes, 2003; Packer et
al., 1991).
We now show that PDE4D deficiency in mice is associ-
ated with a cardiac phenotype comprised of a progressive,
age-related cardiomyopathy and exercise-induced ar-
rhythmias, despite normal global cAMP signaling. Further-
more, PDE4D3 was found to be an integral component
of the RyR2 macromolecular signaling complex. RyR2
located on the sarcoplasmic reticulum (SR) is the major
Cell
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traction coupling in heart muscle. RyR2 channels were
PKA hyperphosphorylated and exhibited a “leaky” phe-
notype in PDE4D-deficient mice, similar to RyR2 de-
fects observed in patients with heart failure and sudden
cardiac death (SCD) (Marx et al., 2000; Wehrens et al.,
2003). In failing human hearts, PDE4D3 levels were re-
duced in the RyR2 complex. Moreover, mice with
PDE4D deficiency exhibited accelerated progression of
heart failure following myocardial infarction associated
with RyR2 channels that were PKA hyperphosphory-
lated and exhibited a “leaky” phenotype. Pharmacolog-
ical PDE4 inhibition was associated with exercise-
induced cardiac arrhythmias that were suppressed in
mice harboring a mutation that prevents PKA phos-
phorylation of the RyR2 channel. Our data suggest that
PDE4D deficiency may contribute to heart failure and
arrhythmias by promoting defective regulation of the
RyR2 channel.
Results
PDE4D Gene Inactivation Causes
Age-Related Cardiomyopathy
To explore the consequences of chronic PDE4D defi-
ciency on cardiac function, we used a mouse model of
PDE4D gene inactivation (Jin et al., 1999). Echocardiog-
raphy of PDE4D−/− mice showed a progressive, age-
dependent increase in left ventricular end-diastolic
diameter (LVEDD), a hallmark of cardiac dysfunction (Fig-
ure 1A; n = 12 each for wild-type [wt] and PDE4D−/−).
PDE4D−/− mice exhibited increased heart-weight-to-
body-weight (HW/BW) ratios compared to wt controls
(Figure 1B). PDE4D−/− mice had reduced ejection frac-
tions (EF) and cardiac contractility (dP/dt)/Pid, docu-
mented by cardiac catheterization (Figures 1C and 1D).
Histologic examination of PDE4D−/− hearts confirmed
that the 15-month-old hearts were dilated, with no
other structural abnormalities (Figure 1E). These data
show that PDE4D deficiency is associated with pro-
gressive cardiac dysfunction consistent with a dilated
cardiomyopathy similar to that seen in patients with
chronic heart failure.
Global cAMP Signaling Is Normal
in PDE4D-Deficient Mice
It is well established that chronic hyperadrenergic sig-
naling is associated with heart failure. Therefore, we
sought to determine whether the mechanism underly-
ing the observed cardiac phenotype in PDE4D−/− mice
was increased global cAMP signaling. However, there
were no significant differences in global cAMP levels
and β-adrenergic receptors in hearts from PDE4D−/−
mice (Figures 2A–2C). Total cAMP-hydrolyzing activ-
ity of PDE in the heart was only slightly decreased
in PDE4D−/− mice (data not shown), consistent with
PDE4D activity representing only a fraction of total cy-
tosolic PDE cAMP-hydrolyzing activity in the heart
(Mongillo et al., 2004; Richter et al., 2005). However,
rolipram-sensitive PDE4 activity in PDE4D−/− heart was
reduced by w50% (data not shown). Whereas global
cAMP signaling was not perturbed in PDE4D-deficient
mice, there was a significant increase in localized
F
o
*
(
c
m
D
(
i
(
m
(
3
P
(
m
i
c
(
a
m
d
P
WcAMP levels at the cardiomyocyte Z line (correspond-igure 1. PDE4D Deficiency Promotes Age-Related Cardiomy-
pathy
p < 0.05 versus wt; #p < 0.05 versus PDE4D−/−.
A) Echocardiography at 3 month intervals showing progressive in-
rease in left ventricular end-diastolic diameter (LVEDD) in PDE4D−/−
ice (open squares, wt; filled squares, PDE4D−/−; n = 12 each).
ata in (A)–(D) are mean ± SEM.
B) Age-dependent increase in heart-to-body-weight ratio (HW/BW)
n PDE4D−/− mice (open bar, wt; filled bar, PDE4D−/−).
C) Age-dependent decrease in ejection fraction (EF) in PDE4D−/−
ice (open bar, wt; filled bar, PDE4D−/−).
D) Reduced cardiac contractility (dP/dt/Pid) in PDE4D−/− mice at
, 9, and 15 months of age (open squares, wt; filled squares,
DE4D−/−).
E) Histology showing dilated cardiomyopathy in PDE4D-deficient
ouse hearts.ng to the location of the RyR2 channel) in cardiomyo-
ytes isolated from PDE4D−/− mice following a low dose
1 nM) of isoproterenol (Figures 2D and 2E). Thus, the
bnormalities observed in cardiac function of PDE4D−/−
ice must be explained by defects in localized cAMP-
ependent signaling.
KA Phosphorylation of RyR2 in PDE4D−/− Mice
hile many proteins in the heart are regulated by PKAphosphorylation and therefore can be affected by al-
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27Figure 2. Normal cAMP and β-Adrenergic-
Receptor Levels in PDE4D−/− Mouse Hearts
and Increased cAMP Levels at the Z Lines
Detected by FRET-PKA
(A) cAMP concentrations were not significantly
increased in hearts of 3- to 6-month-old
PDE4D−/− mice (wt, n = 5; PDE4D−/−, n = 5; p =
NS). Each heart was extracted and assayed
separately in quadruplicate experiments. Data
in (A), (B), and (E) are mean ± SD.
(B) β-adrenergic-receptor density was un-
changed in PDE4D−/− mice (wt, n = 5;
PDE4D−/−, n = 5; p = NS).
(C) Comparison of the Bmax values for β-adren-
ergic-receptor density calculated separately
for each of the five wt or five PDE4D−/− knock-
out mice investigated.
(D) FRET-PKA showing increased cAMP-
dependent signal over the Z lines (site of
localization of RyR2) after low-dose isopro-
terenol stimulation in PDE4D−/− cardiomyo-
cyte when compared to wild-type cardiomyocyte (white and black areas represent sensing of highest and lowest cAMP concentrations, re-
spectively).
(E) Bar graph summarizes Z line intensity-profile analysis of 480 nm/545 nm intensity ratio from five wt and six PDE4D−/− cells
(*p < 0.05). Dimensions as indicated.tered PDE4D gene expression, only a limited number of
these PKA substrates are known to be dysregulated by
PKA during heart failure. For example, it has been
shown that PKA phosphorylation of phospholamban, a
regulator of the SR Ca2+ uptake pump (SERCA2a), is
decreased in heart failure. In contrast, of the other pro-
teins known to be involved in regulating cardiac con-
tractility, the SR Ca2+-release channel, RyR2, has been
shown to be PKA hyperphosphorylated in heart failure
(Antos et al., 2001; Marx et al., 2000; Reiken et al.,
2003a, 2003b; Yano et al., 2000, 2003), although this
finding has been challenged by others (Jiang et al.,
2002).
Given that RyR2 PKA hyperphosphorylation has been
linked to cardiac dysfunction in humans and animal
models and that cAMP concentrations are increased in
the compartment of RyR2 Ca2+ release (Figures 2D and
2E), we sought to determine whether RyR2 PKA hyper-
phosphorylation might play a role in the observed
cardiac phenotype in PDE4D−/− mice. Indeed, there was
a progressive, age-dependent increase in PKA phos-
phorylation of RyR2 on Ser2808 (detected using a
phosphoepitope-specific antibody) in PDE4D−/− mouse
hearts (Figures 3A and 3B). PKA hyperphosphorylation
of RyR2 in PDE4D−/− mouse hearts was associated with
depletion of the RyR2-stabilizing protein calstabin2
(FKBP12.6) that prevents Ca2+ leak from the SR into the
cytosol through RyR2 during diastole in the heart (Fig-
ure 3C) (Marx et al., 2000; Wehrens et al., 2003). In-
creased PKA phosphorylation of RyR2 was not caused
by increased protein levels of PKA catalytic and regula-
tory subunits in the RyR2 complex (Figure 3A). More-
over, no changes in PP1 or PP2A phosphatase levels
in the RyR2-complex levels were detected (data not
shown). Phosphorylation of RyR2 by another kinase
that phosphorylates the channel, Ca2+/calmodulin-
dependent protein kinase A (CaMKII) (detected using a
phosphoepitope-specific antibody), was not altered in
PDE4D−/− mouse hearts (Figures 3A and 3D).
In wt mice, PDE activity was associated with immu-
noprecipitated RyR2 channels (Figure 3E). RyR2-asso-ciated PDE activity was almost completely inhibited by
the PDE4 antagonist rolipram but not by the PDE3 in-
hibitor milrinone. Moreover, PDE activity specifically as-
sociated with RyR2 channels was reduced to zero in
the PDE4D−/− mice (Figure 3E). Taken together, these
data suggested that one consequence of PDE4D defi-
ciency is PKA hyperphosphorylation of RyR2, which
has previously been associated with heart failure (Marx
et al., 2000). Moreover, it appeared that the PDE activity
associated with the RyR2 complex was encoded by the
PDE4D gene.
Abnormal RyR2 Channels in PDE4D-Deficient Hearts
To ascertain the functional consequences of PKA hy-
perphosphorylation of RyR2 in hearts from PDE4D-defi-
cient mice, we examined the single-channel properties
of RyR2 in planar lipid bilayers. Compared to channels
from wt mice, RyR2 from PDE4D−/− mice exhibited
significantly increased open probability (Po) and fre-
quency of openings (Fo) and decreased mean open and
closed times when channels were examined under con-
ditions that mimic diastole in the heart (cytosolic (cis)
[Ca2+] 150 nM) (Figures 3F and 3G). Thus, PKA hyper-
phosphorylation of cardiac RyR2 in PDE4D-deficient
mice was associated with the same defects in RyR2-
channel function (“leaky” channels) previously linked
to human heart failure (Marx et al., 2000) and geneti-
cally determined exercise-induced sudden cardiac death
(Wehrens et al., 2003).
PDE4D3 Is a Component of the RyR2
Macromolecular Complex
The finding that the PDE activity that coimmunopre-
cipitates with RyR2 was abrogated in channels from
PDE4D−/− mouse hearts (Figure 3E) raised the possi-
bility that a protein encoded by the PDE4D gene is an
integral component of the RyR2 macromolecular sig-
naling complex. Four genes constitute the type 4 phos-
phodiesterase family (PDE4A, PDE4B, PDE4C, and
PDE4D), and all are expressed as multiple splice vari-
ants (Conti et al., 2003; Houslay and Adams, 2003). With
Cell
28Figure 3. Age-Dependent Alterations in RyR2-Channel Complex and Function in PDE4D−/− Murine Heart
(A) Immunoblots showing progressive increase in PKA phosphorylation of RyR2 at Ser2808 (second panel) but no change in CaMKII phosphor-
ylation at Ser2814 (third panel) and progressive decrease in calstabin2 binding to the RyR2 complex (fourth panel). PKA catalytic (-C) and
regulatory (-RII) subunits are not changed during heart failure (HF) development (fifth and six panels).
(B) Quantification of age-dependent increase in RyR2 PKA phosphorylation (open bars, wt; filled bars, PDE4D−/−; *p < 0.05 versus wt, #p <
0.05 versus PDE4D−/−). Data in (B)–(E) and (G) are mean ± SD.
(C) Quantification of age-dependent decrease in calstabin2 in the RyR2 complex (open bars, wt; filled bars, PDE4D−/−; *p < 0.05 versus wt,
#p < 0.05 versus PDE4D−/−).
(D) Quantification of CaMKII-specific RyR2 phosphorylation showing no significant changes with aging.
(E) Immunoprecipitation of RyR2 showing complete absence of PDE activity in the RyR2 complex in PDE4D−/− mouse hearts. *p < 0.05 versus
wt; #p < 0.05 versus untreated wt. Rol, rolipram; Mil, milrinone.
(F) Single-channel recordings of wt (left) and PDE4D−/− RyR2 (right) at 3 months of age (top) and 15 months of age (bottom). Current trace
from 3-month-old PDE4D−/− heart shows slightly increased channel open probability (Po) with short openings consistent with increased PKA
phosphorylation. At 15 months of age, RyR2 channels from PDE4D−/− hearts showed significantly increased Po and subconductance states
(indicated by dotted lines), as evidenced by current-amplitude histograms. Upper traces represent 5 s; lower traces represent 500 ms.
Channel openings are upward; full openings are 4 pA; closed state is indicated by “c.”
(G) Bar graphs summarizing Po, open frequency (Fo), average open time (To), and average closed time (Tc) at 15 months of age in wt and
PDE4D−/− groups. *p < 0.001; n = 10 each.
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PDE3-specific inhibitor, decreased RyR2-associated PDE activitythe recent discovery of additional PDE4D variants (Gre-
tarsdottir et al., 2003; Wang et al., 2003), a total of nine
PDE4D splice variants (PDE4D1–9) are known (Richter
et al., 2005). We generated an isoform-specific anti-
body against the unique N-terminal epitope of PDE4D3
(Figure 4A). PDE4D splice variants were identified by
RT-PCR in heart (data not shown), and PDE4D3,
PDE4D8, and PDE4D9 expression in the heart was
demonstrated using isoform-specific antibodies (Figure
4B), confirming that these are the major PDE4D iso-
forms expressed in heart muscle (Richter et al., 2005).
To examine the possibility that a specific PDE4D iso-
form is part of the cardiac RyR2 channel complex, im-
munoprecipitations were performed using human heart
extracts. RyR2 channels were immunoprecipitated with
anti-RyR2 antibody and assayed for coimmunoprecipi-
tation of PDE4D3, PDE4D8, or PDE4D9 with RyR2 by
immunoblotting. Using isoform-specific PDE4D anti-
bodies, only PDE4D3 was detected in the RyR2 com-
plex. In addition, anti-PDE4D3 antibody was used to
coimmunoprecipitate RyR2 (Figure 4B). The interaction
between PDE4D3 and RyR2 was specific because
PDE4D3 was excluded from immunoprecipitates us-
ing control IgG (Figure 4B). Moreover, we used the
PDE4D3-specific antibody to show that total PDE4D3
protein was decreased w37% in haploinsufficient
PDE4D+/− mouse hearts and by 100% in homozygous
PDE4D−/− hearts (Figure 4C). Finally, PDE4D3 in the
RyR2 macromolecular signaling complex was also de-
creased by w44% in PDE4D+/− mouse hearts and by
100% in PDE4D−/− heart (Figure 4D). Taken together,
these data show that PDE4D3 is an integral component
of the RyR2 macromolecular complex in the heart and
that PDE4D3 is the only PDE isoform in the RyR2
complex.
PDE4D3 Is Decreased in the RyR2 Complex
in Failing Human Hearts
PDE4D3 was also associated with RyR2 from human
hearts (Figure 5A). In human heart failure (HF), PDE4D3Figure 4. PDE4D3 Is a Component of the
RyR2 Ca2+-Release-Channel Complex
(A) PAN-PDE4 antibody against the con-
served UCR2 domain (α-4PAN, top panel)
and antibody raised against the N-terminal
domain unique to PDE4D3 (α-4D3, bottom
panel) were used to detect PDE4D isoforms
in extracts of COS7 cells overexpressing re-
combinant PDE4D splice variants 1 to 9.
Samples were size fractionated on 6% SDS-
PAGE and blotted onto Immobilon-P mem-
branes.
(B) Immunoblotting with splice-variant-spe-
cific anti-PDE4D3, anti-PDE4D8, and anti-
PDE4D9 antibodies shows expression of all
three major forms in the heart. However,
immunoprecipitation of RyR2 followed by
splice-variant-specific immunoblot demon-
strates that only PDE4D3 is associated with
RyR2. Reverse immunoprecipitation with a
specific anti-PDE4D3 antibody confirms that
PDE4D3 is physically associated with RyR2.
(C) Immunoblots of cardiac lysates showing
amounts of RyR2 and PDE4D3 in wt, PDE4D+/−, and PDE4D−/− mice. Bar graph shows a 37% reduction of PDE4D3 in the RyR2 complex in
cardiac lysates of PDE4D+/− mice relative to wt. *p < 0.05, n = 3 for each genotype. Data in (C) and (D) are mean ± SD.
(D) Coimmunoprecipitation using anti-RyR2 antibody, showing a 44% decrease of PDE4D3 bound to RyR2 in PDE4D+/− mouse hearts relative
to wt. *p < 0.05, n = 3 for each genotype.Figure 5. Reduced PDE4D3 in the RyR2 Complex in Human Heart
Failure
(A) PDE4D3 was detected in human cardiac lysate and in the immu-
noprecipitated RyR2 complex (IP:RyR2); IP:IgG, negative control.
(B) RyR2 was immunoprecipitated from cardiac homogenates of
normal human (N) and heart failure (HF) samples. PDE4D3 bind-
ing to RyR2 was significantly decreased in human HF. Increased
PKA phosphorylation was detected by a phosphoepitope-specific
RyR2-Ser2808 antibody in HF samples.
(C) RyR2 bound PDE4D3 activity was significantly decreased in HF,
as evidenced by close-proximity substrate cAMP catalysis (#p <
0.001). Data in (C) and (D) are mean ± SD.
(D) Rolipram (R), a PDE4-specific inhibitor, but not milrinone (M), asubmaximally; C, control (#p < 0.001 versus untreated sample).
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30levels in the RyR2 complex were decreased by 43%
(normal, n = 6 versus HF, n = 9; p < 0.001), and the RyR2
channels in the human HF samples were PKA hyper-
phosphorylated (Figure 5B). We have previously shown
that PKA hyperphosphorylation of RyR2 depletes cal-
stabin2 from the RyR2 complex and significantly in-
creases channel activity, consistent with a diastolic SR
Ca2+ leak in human heart failure (Marx et al., 2000; Rei-
ken et al., 2003a). The cAMP-hydrolyzing activity of
RyR2 bound PDE4D3 was decreased by 42% in human
HF samples (n = 6, each experiment was performed in
triplicate; p < 0.001), providing a possible explanation
for chronic RyR2-Ser2808 PKA hyperphosphorylation
observed in failing human hearts (Figure 5C). This re-
duction in PDE4D3 activity in the human HF RyR2 com-
plex was comparable to that observed in the RyR2
complexes in PDE4D+/− mice (Figure 4D). To explore the
basis for the observed reduction in PDE4D3 amount
and activity in the HF RyR2 complex, we examined PKA
phosphorylation of PDE4D3, which has been shown to
increase its activity (Sette and Conti, 1996) and binding
to mAKAP (Carlisle Michel et al., 2004). We observed a
w40% reduction in PKA phosphorylation of PDE4D3 in
the human HF RyR2 complexes compared to nonfailing
controls (n = 3, p < 0.01), providing a possible explana-
tion for the observed decrease in amount and activity of
PDE4D3 in the HF RyR2 complexes (data not shown).
PDE4-specific inhibition with rolipram (10 M) signifi-
cantly decreased RyR2 bound PDE4D3 activity in nor-
mal human heart lysates (n = 3, p < 0.01), whereas the
PDE3-specific inhibitor milrinone (10 M) had no effect
on RyR2-associated PDE activity (Figure 5D), confirm-
ing that the cAMP-hydrolyzing activity in the RyR2
complex is due to PDE4. Thus, PDE4D3 is part of
the human RyR2 signaling complex, and reduction of
PDE4D3 activity in heart failure may contribute to RyR2
PKA hyperphosphorylation and diastolic SR Ca2+ leak
observed in failing hearts (Shannon et al., 2003).
Cardiac Arrhythmias due to PDE4 Inhibition Are
Suppressed in Mice Harboring RyR2
that Cannot be PKA Phosphorylated
We have previously demonstrated a link between PKA
hyperphosphorylation of RyR2, “leaky” RyR2 channels,
and exercise-induced sudden cardiac death (Wehrens
et al., 2003). Therefore, in the present study, we sought
to determine whether PDE4D-deficient mice, which ex-
hibit PKA-hyperphosphorylated RyR2, are more sus-
ceptible to exercise-induced cardiac arrhythmias. Rest-
ing heart rate in PDE4D−/− mice at 3–4 months of age
was similar to wt, consistent with unchanged baseline
sympathetic activity (wt 584 ± 22 bpm, PDE4D−/− 603 ±
32 bpm; p = NS). Since PDE inhibitors increase arrhyth-
mogenic sudden cardiac death (Barnes, 2003; Packer
et al., 1991), we tested the susceptibility of PDE4D−/−
mice to cardiac arrhythmias during exercise followed
by low-dose epinephrine injection (0.1 mg/kg) using a
previously established protocol (Wehrens et al., 2003,
2004). Exercise-induced sustained (sVT) and nonsus-
tained ventricular arrhythmias (nsVT) were observed in
66% and 100% of PDE4D−/− mice, respectively, but in
none of the wt mice (Figure 6A; each n = 6, p < 0.01).
In order to investigate whether a diastolic SR Ca2+
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oigure 6. Cardiac Arrhythmias due to PDE4D3 Inhibition Are Sup-
ressed in Mice Harboring Mutant RyR2 that Cannot be PKA Phos-
horylated
A) Susceptibility to exercise-induced sustained ventricular arrhyth-
ias (sVT) and nonsustained ventricular arrhythmias (nsVT) was
ignificantly increased in PDE4D−/− compared to wt mice (each n =
, *p < 0.05).
B) Rolipram (0.3 mg/kg body weight) maximally increased RyR2-
er2808 PKA phosphorylation during exercise in vivo. Treatment as
ndicated on top: Rol, rolipram; Epi, epinephrine (0.1 mg/kg); white
ars, no rolipram; black bar, rolipram-treated mice; *p < 0.05 be-
ween treatments in wt mice; #p < 0.001 wt versus homozygous
yR2-S2808A knockin (S2808A+/+) mice. Control mice were treated
ith placebo (rolipram carrier, 0.5% DMSO). Data are mean ± SD.
C) In rolipram-treated mice, susceptibility to exercise-induced sus-
ained ventricular arrhythmias (sVT) and nonsustained ventricular
rrhythmias (nsVT) was significantly decreased in homozygous
yR2-S2808A knockin (S2808A+/+) mice compared to wt mice
each n = 6, #p < 0.05).
D) Mortality from sudden death was significantly increased in
DE4D+/− mice 24 and 72 hr after MI compared to wt mice. White
ars, wt mice; black bars, PDE4D+/− mice. *p < 0.01 between wt
nd PDE4D+/− groups.eak due to PKA hyperphosphorylation of RyR2 directly
ontributes to a cardiac phenotype in PDE4D−/− mice,
e treated wt mice with the PDE4 inhibitor rolipram.
olipram (0.3 mg/kg) inhibited cAMP-hydrolyzing PDE
ctivity in the RyR2 complex in wt mice (data not
hown) and resulted in significantly increased RyR2
KA phosphorylation during exercise (Figure 6B). Fol-
owing exercise and epinephrine injection (0.1 mg/kg),
entricular arrhythmias or sudden death occurred in
00% of rolipram-treated wt mice (Figure 6C). Impor-
antly, RyR2-S2808A knockin mice, which express a
utant RyR2 that cannot be PKA phosphorylated (Fig-
re 6B), were protected against rolipram-induced exer-
ise-triggered arrhythmias (Figure 6C). These findings
ndicate that the proarrhythmogenic effects of PDE4 in-
ibition are specifically due to PKA hyperphosphoryla-
ion of RyR2 at Ser2808. Thus, PKA phosphorylation
f RyR2 at Ser2808 is necessary in order to generate
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31triggered cardiac arrhythmias associated with PDE4 in-
hibition. Moreover, mortality due to sudden cardiac
death at 24 and 72 hr following myocardial infarction
(MI, induced by ligation of the left anterior descending
artery) was significantly increased in PDE4D+/− com-
pared to wt mice (Figure 6D), further suggesting that
PDE deficiency in the RyR2-channel complex increases
susceptibility to cardiac arrhythmias.
Exacerbation of Acute Heart Failure Associated with
PDE4D3 Deficiency Is Attenuated in Mice Harboring
RyR2 that Cannot be PKA Phosphorylated
Since PDE4D3 protein levels and cAMP-hydrolyzing ac-
tivity in the RyR2 complex were reduced by 42% and
43% in human heart failure, respectively, we examined
whether a partial reduction of PDE4D in haploinsuffi-
cient PDE4D+/− mice affects progression of HF. Hetero-
zygous PDE4D+/− and wt control mice were subjected
to proximal left anterior descending (LAD) coronary ar-
tery ligation to induce myocardial infarction (MI), which
results in progressive heart failure. Similar to human
heart failure (Figure 5B), PDE4D+/− mice had a 44% re-
duction of PDE4D3 bound to the RyR2 complex as
compared to control (Figure 4D) and developed signifi-
cantly worse heart failure manifested by a larger in-
crease in cardiac dimensions and more depressed
cardiac contractility over a 28 day post-MI period (Fig-
ure 7). Cardiac dimensions (LVEDD) were 30% larger in
PDE4D+/− hearts compared to wt 28 days post-MI (Fig-
ure 7A), consistent with more severe cardiomyopathy.
Infarct sizes were not significantly different in 4- to
5-month-old wt (35.8% ± 3.1% LV, n = 11) and PDE4D+/−
mice (37.2% ± 3.7% LV, n = 14). Cardiac function, mea-
sured by echocardiography and cardiac catheteriza-
tion, was reduced in haploinsufficient PDE4D+/− mice
compared with wt mice following MI (Figures 7B and
7C). Accelerated HF progression in PDE4D+/− mice was
associated with enhanced RyR2 PKA hyperphosphory-
lation and reduced PDE4D3 protein levels in the RyR2
complex (Figures 7D and 7E) and significantly reduced
PDE4D3 enzymatic activity in the RyR2 complex (Figure
7F). In the RyR2 complex, PKA catalytic and regulatory
subunits, as well as the levels of the protein phospha-
tases PP1 and PP2A, were not significantly different be-
tween wt and PDE4D+/− hearts (data not shown). Thus,
reduction of PDE4D3 activity in the RyR2 complex in
haploinsufficient PDE4D+/− mice to levels similar to
those observed in RyR2 complexes from failing hu-
man hearts results in accelerated progression of heart
failure.
We next set out to determine whether the detrimental
effects of PDE4D deficiency in the heart were depen-
dent on dysfunction of the RyR2-channel complex due
to PKA hyperphosphorylation and reduced binding of
calstabin2. Since recent studies have demonstrated
that the 1,4-benzothiazepine JTV-519 increases the
binding of calstabin2 to RyR2 in vivo, we treated
PDE4D+/− mice subjected to myocardial infarction with
JTV-519. Treatment with JTV-519 (symbols) significantly
increased the amount of calstabin2 bound to RyR2
(Figure 7D) and was associated with improved cardiac
function following MI (Figures 7B and 7C). We also
crossed the PDE4D+/− mice with RyR2-S2808A mice toinvestigate the specific role of PKA hyperphosphoryla-
tion of RyR2 in the development of cardiac dysfunction
in PDE4D+/− mice. RyR2-S2808A mice harbor RyR2 that
cannot be PKA phosphorylated (Figure 7D). Prevention
of PKA hyperphosphorylation improved cardiac func-
tion in PDE4D+/− mice subjected to MI (Figures 7A
and 7C, green line and bars). Infarct sizes were not sig-
nificantly different between PDE4D+/− mice, PDE4D+/−
mice treated with JTV-519 (38.6% ± 3.9% LV, n = 12),
or PDE4D+/− mice crossed with RyR2-S2808A mice
(39.8% ± 4.3% LV, n = 11). These data demonstrate that
normalizing RyR2 function, either by enhancing cal-
stabin2 binding to RyR2 or by preventing PKA hyper-
phosphorylation of RyR2, improved cardiac function in
PDE4D+/− mice following myocardial infarction. Taken
together, these data suggest that the cardiac defects
observed in PDE4D-deficient mice are due, at least in
part, to defective RyR2 function.
Discussion
The present study shows that phosphodiesterase
(PDE4D) deficiency is associated with a severe cardiac
phenotype consisting of heart failure and lethal cardiac
arrhythmias. The importance of this cardiac phenotype
in PDE4D-deficient mice is underscored by the fact that
it is similar to that observed in humans with heart fail-
ure: decreased cardiac function and increased suscep-
tibility to cardiac arrhythmias. Moreover, PDE inhibition
has been associated with increased mortality in pa-
tients with heart failure (Packer et al., 1991), arrhyth-
mias, and sudden cardiac death (Bittar and Friedman,
1991; Suissa et al., 1996), although the mechanism has
been unknown. Finally, since PDE4 inhibitors are being
tested in clinical trials to treat common chronic dis-
eases including Alzheimer’s disease (Gong et al., 2004),
asthma, and COPD (Giembycz, 2002), it is important to
understand the consequences of long-term inhibition
of PDE4 activity in the heart, where PDE4 activity plays
a major role in regulating cAMP-dependent signals
(Perry et al., 2002; Verde et al., 1999; Xiang et al., 2005).
Since the PDE4D deficiency caused no detectable al-
teration in global cAMP levels or β-adrenergic signaling
in the heart, the cardiac phenotype in PDE4D−/− mice
must be due to abnormalities in localized signaling, i.e.,
altered microdomains of cAMP, which is supported by
our FRET imaging data showing increased cAMP con-
centrations at the Z lines of PDE4D-deficient cardio-
myocytes (where RyR2 is present) after physiologic
stimulation of β-adrenergic receptors. Indeed, the con-
cept that localized signaling regulates cAMP in the
heart is supported by previous findings showing that
PDE4 is a localized regulator of β-adrenergic receptor
(β2-AR) signaling in cardiomyocytes (Baillie et al., 2003;
Mongillo et al., 2004; Perry et al., 2002; Xiang et al.,
2005). Moreover, it has been shown that PDE4D3 can
be targeted to specific compartments including the
cardiomyocyte Z line via the targeting protein mAKAP
(Carlisle Michel et al., 2004; Dodge et al., 2001; Sette
and Conti, 1996; Yang et al., 1998). Our experiments
were carefully designed to examine differences in
cAMP levels at the Z line in cardiomyocytes from wt
versus PDE4D-deficient mice using low-dose β-adren-
Cell
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Progression
(A) LVEDD increased in PDE4D+/− (black
squares) compared to wt (open squares)
mice before (control, CO) and 14 and 28
days after myocardial infarction (MI) (*p <
0.05 versus wt). Both treatment with the 1,4-
benzothiazepine JTV-519 (red line), which
enhances calstabin2 binding to RyR2, or
crossing the PDE4D+/− mice with RyR2-
S2808A mice that harbor RyR2 that cannot
be PKA phosphorylated (green line) signifi-
cantly reduced the remodeling of the left
ventricle following MI (#p < 0.01 versus
PDE4D+/−). Data in (A)–(C) are mean ± SEM.
(B) Reduced cardiac EF in PDE4D+/− mice 28
days after MI. wt, open bars; PDE4D+/− mice,
filled bars (*p < 0.05 versus CO same geno-
type). Both treatment with the 1,4-benzothi-
azepine JTV-519 (red bar), which enhances
calstabin2 binding to RyR2, or crossing the
PDE4D+/− mice with RyR2-S2808A mice that
harbor RyR2 that cannot be PKA phosphory-
lated (green bar) significantly improved left
ventricular EF following MI (#p < 0.01 versus
PDE4D+/− MI).
(C) Left ventricular contractility (dP/dt)/Pid
normalized to 100% of control in wt (open
bars) and haploinsufficient PDE4D+/− mice
(black bars) before (control, CO) and 28 days
after MI (*p < 0.05 versus CO in same genotype). Treatment with JTV-519 (red bar) or crossing the PDE4D+/− mice with RyR2-S2808A mice
(green bar) significantly improved contractility following MI (#p < 0.01 versus PDE4D+/− MI).
(D) Immunoblot showing levels of PDE4D3, calstabin2, and RyR2-Ser2808 PKA phosphorylation in the immunoprecipitated RyR2-channel
complex. JTV-519 treatment (red) or crossing the PDE4D+/− mice with RyR2-S2808A mice (green) significantly increased the binding of
calstabin2 to RyR2 in the PDE4D-deficient mice.
(E) Quantification of RyR2 PKA phosphorylation in wt and PDE4D+/− mice before (CO) and 28 days after MI, showing significantly more RyR2
PKA hyperphosphorylation in PDE4D+/− mice (*p < 0.05 versus wt at same time point). Treatment with JTV-519 (red bar) or crossing the
PDE4D+/− mice with RyR2-S2808A mice (green bar) significantly reduced RyR2 PKA phosphorylation following MI (#p < 0.01 versus PDE4D+/− MI).
Data in (E) and (F) are mean ± SD.
(F) Quantification of RyR2-associated PDE activity showing significant decrease in PDE4D+/− mice 28 days before (CO) and after MI compared
to wt (*p < 0.05 versus wt). Treatment with JTV-519 (red bar) or crossing the PDE4D+/− mice with RyR2-S2808A mice (green bar) significantly
increased RyR2-associated PDE activity following MI (#p < 0.01 versus PDE4D+/− MI).ergic stimulation (1 nM isoproterenol). Others have
shown that nonspecific pharmacologic PDE inhibition
using maximal β-adrenergic stimulation causes cAMP
spillover into different compartments (Zaccolo and
Pozzan, 2002).
There are likely many changes in cAMP-dependent
signaling in the hearts of PDE4D-deficient mice. For ex-
ample, receptor-stimulated β-arrestin-mediated recruit-
ment of PDE4 regulates G protein switching by the β2-
AR in cardiomyocytes (Baillie et al., 2003). Moreover,
PDE4D is an integral component of the β2-AR signaling
complex (Xiang et al., 2005). Loss of other PDE4D iso-
forms (e.g., PDE4D8 and PDE4D9) likely also contrib-
utes to localized alterations in cAMP levels in PDE4D−/−
cardiomyocytes (Richter et al., 2005). Our work shows
that PKA phosphorylation of RyR2, which occurs at an
early stage, before any structural or functional abnor-
malities were observed in PDE4D−/− mouse hearts (Fig-
ure 3), is a critical event since crossing the PDE4D-
deficient mice with RyR2-S2808A mice inhibits the
development of the cardiac phenotype (Figures 6 and 7).
Indeed, there are at least two lines of evidence that
strongly suggest that the cardiac phenotype in PDE4D-
deficient mice is due to defects related to PKA hyper-
phosphorylation of RyR2 and the resulting abnormal
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re following myocardial infarction. This suggests that
DE4D deficiency in the RyR2 complex may play a role
n PKA hyperphosphorylation of the channel and the
ssociated cardiomyopathy. Second, and more impor-
antly, sustained cardiac arrhythmias associated with
harmacologic PDE4 inhibition and accelerated pro-
ression of heart failure following MI were not observed
n RyR2-S2808A mice harboring a RyR2 that cannot be
KA phosphorylated (Figures 6 and 7). Thus, the pre-
ent study indicates that the cardiac phenotype in
DE4D-deficient mice is directly related to defective
egulation of RyR2 and provides support for the model
hereby PKA hyperphosphorylation of RyR2 causes a
iastolic SR Ca2+ leak that (1) depletes SR Ca2+, con-
ributing to decreased cardiac function (Marx et al.,
000), and (2) may provide a trigger for fatal cardiac
rrhythmias (Wehrens et al., 2003).
Since the role of PKA hyperphosphorylation of RyR2
n heart failure (Jiang et al., 2002) has been challenged,
t is important to establish a mechanism underlying the
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33PKA hyperphosphorylation of RyR2 and to show that
this defect can specifically account for the observed
cardiac phenotype. We now show that PDE4D3 defi-
ciency in the RyR2 complex contributes to PKA hyper-
phosphorylation of RyR2 in human and animal heart
failure. Furthermore, a mutant RyR2 that cannot be PKA
phosphorylated (RyR2-S2808A) protects against the
cardiac effects of PDE4D3 deficiency in the RyR2 com-
plex in vivo. Indeed, the finding that PDE4D3 is de-
creased in RyR2 complexes in human heart failure
helps address one of the controversial issues in this
field, the mechanism whereby RyR2 become PKA hyp-
erphosphorylated (Marx et al., 2000) despite decreases
in global cAMP levels in failing human hearts (Regitz-
Zagrosek et al., 1994).
The current findings suggest a novel function of
PDE4D3 in the regulation of RyR2, the major intracellu-
lar Ca2+-release channel in the heart. PDE4D3 activity
provides an important negative-feedback mechanism
to limit β-AR-dependent PKA phosphorylation of RyR2-
Ser2808. Under physiologic conditions, PDE4D3 may
regulate local PKA activity and channel activation via
phosphorylation of RyR2-Ser2808, thereby preventing
excess accumulation of cAMP (Zaccolo and Pozzan,
2002) and uncontrolled PKA-mediated activation of the
channel. In human heart failure, loss of negative feed-
back due to PDE4D3 deficiency in the RyR2 complex
likely contributes to RyR2 PKA hyperphosphorylation;
calstabin2 depletion; and hyperactive, “leaky” RyR2
channels (Marx et al., 2000; Pieske et al., 1999). Taken
together, our data suggest that PDE4D3 plays a pro-
tective role in the heart against heart failure and ar-
rhythmias.
These data further suggest that chronic pharmaco-
logic PDE4 inhibition could contribute to a cardiac phe-
notype including cardiac dysfunction and arrhythmias,
particularly in individuals with underlying cardiac dis-
ease. In addition, other signaling systems may be af-
fected by reduced PDE4D activity, e.g., β-arrestin tar-
geting of PDE4D3 activity may be important for β2-AR
desensitization (Perry et al., 2002). Importantly, PDE4D3
deficiency and pharmacologic PDE4 inhibition with roli-
pram was associated with stress-induced cardiac ar-
rhythmias, which did not occur in mice lacking the
RyR2 PKA phosphorylation site at Ser2808. These find-
ings suggest that PDE4 inhibitors could increase the
risk of cardiac arrhythmias due to “leaky” RyR2 chan-
nels as observed in individuals with genetic forms of
sudden cardiac death linked to RyR2 mutations (Lehn-
art et al., 2004; Wehrens et al., 2003) and in patients
with heart failure.
Experimental Procedures
PDE4D–/– Mice and RyR2-S2808A Knockin Mice
PDE4D–/– mice were generated and genotyped as described (Jin et
al., 1999). RyR2-S2808A knockin mice (see the Supplemental Data
available with this article online for details), generated using homol-
ogous recombination, exhibited normal cardiac structure and func-
tion, and no PKA phosphorylation of RyR2 was detected using a
kinasing reaction with [γ-32P]ATP or with a phosphoepitope-spe-
cific antibody that detects PKA-phosphorylated RyR2.
Transthoracic Echocardiography and In Vivo
Hemodynamic Analyses on Mice
Transthoracic 2D echocardiography and in vivo hemodynamic
analyses on mice were performed as previously described (Weh-rens et al., 2005) (see Supplemental Data for details). All animal
studies were performed according to protocols approved by the
Institutional Animal Care and Use Committee of Columbia Univer-
sity and according to NIH guidelines.
Myocardial Infarct Model
PDE4D–/– and age-and-litter-matched wild-type mice (4 to 5 months
old) were anesthetized with 1.5% isoflurane and ventilated with a
small-rodent respirator (Harvard Apparatus). A left thoracotomy
was performed, and the left anterior descending artery (LAD) was
ligated proximally with an 8-0 suture as described (Wehrens et al.,
2005).
Exercise Testing and Mouse ECG Recording
Ambulatory ECG recordings were performed using implantable ra-
diotelemetry transmitters (DSI) as described (Wehrens et al., 2004).
For the pharmacological experiments performed in wt and RyR2-
S2808A knockin mice, animals were pretreated for 30 min by in-
traperitoneal injection with the PDE4 inhibitor rolipram (0.3 mg/kg)
or placebo (DMSO 0.5% as carrier) followed by the exercise proto-
col described above.
-Adrenergic-Receptor Measurements
β-adrenergic-receptor levels were assessed as previously de-
scribed (Reiken et al., 2003b) (see Supplemental Data for details).
Immunoprecipitation and Immunoblot Analysis
RyR2 channels were immunoprecipitated and immunoblotted as
previously described (Marx et al., 2000) (see Supplemental Data
for details).
Phosphodiesterase Activity Assay
Phosphodiesterase (PDE) activity was measured using selective
binding of 5#-AMP to yttrium silicate beads with embedded scintil-
lant. Immunoprecipitated RyR2 complexes were incubated with 50
nM 3H-cyclic nucleotide (Amersham, 5–60 Ci/mM) in 50 mM Tris-
HCl (pH 7.5), 8.3 mM MgCl2, 1.7 mM EGTA, BSA 0.01% at 30°C for
30 min. The reaction was terminated by adding one-third of 5 mg/
ml yttrium silicate beads in 18 mM Zn acetate/Zn sulfate solution
(3:1). After 30 min, hydrolysis was quantified by a scintillation
counter (Wallac 1409, PerkinElmer).
FRET-PKA Assay
Local intracellular cAMP concentrations were determined in murine
cardiomyocytes using fluorescence resonance energy transfer
(FRET) between the cyan (CFP) and yellow (YFP) variants of green
fluorescent protein as described (Zaccolo and Pozzan, 2002) (see
Supplemental Data for details).
Back Phosphorylation of PDE4D3
PKA phosphorylation of PDE4D3 was assessed using a kinasing
reaction on PDE4D3 immunoprecipitated from 100 g of human
cardiac homogenates (see Supplemental Data for details).
Single-Channel Recordings
RyR2 single channels were recorded in planar lipid bilayers as pre-
viously described (Marx et al., 2000). Symmetrical solutions used
were (in mM) trans-HEPES 250 and Ca(OH)2 53 (pH 7.35) and cis-
HEPES 250, Tris 125, EGTA 1.0, and CaCl2 0.5 (pH 7.35). Free Ca2+
concentrations were calculated by CHELATOR software. At the
conclusion of each experiment, ryanodine (5 M) or ruthenium red
(20 M) was applied to confirm RyR2-channel identity.
PKA Phosphorylation of Cardiac Ryanodine Receptors
PKA phosphorylation of RyR2 was assessed as previously de-
scribed (Marx et al., 2000) (see Supplemental Data for details).
Statistical Analysis
Data are reported as mean ± SEM for in vivo experiments and
mean ± SD for biochemical studies. Differences between multiple
experimental groups were compared by analysis of variance
(ANOVA) followed by Tukey’s multiple comparison test. Analysis
between two groups was performed by t test (paired or unpaired
Cell
34as appropriate). Serial studies were tested by repeated-measure
ANOVA. A value of p < 0.05 was considered significant.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures
and Supplemental References and can be found with this article
online at http://www.cell.com/cgi/content/full/123/1/25/DC1/.
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